CTOS 2020 was conducted virtually from November 18th through the 21st, given the nature of our current environment, much of the content of the conference centered on COVID-19 and its impact on cancer patients, but there were a number of sessions and presentations and posters devoted to GIST as well.
Over fifty participants attended a virtual meeting of SDH Experts in honor of GIST Awareness Day, July 13th, during Virtual Life Fest 2020. Questions were presented to the panel which included One of the first questions asked was “what specifically are your most challenging research hurdles and how can we, as patients and patient advocates from around the world help move research forward?”
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Julie Durkee shares her story.
GIST experts provided updates and answered questions on GIST research and new GIST therapies.
When facing a diagnosis of cancer, self-advocacy becomes an important survival skill for patients and caregivers. These stories illustrate what an ordinary person can accomplish due to extraordinary circumstances and how they affected change for so many people with GIST.
Dr. Andrew Blakely, Program Director, Surgical Oncology Research Fellowship, National Cancer Institute, National Institutes of Health, shares how his team works with adult SDH-deficient GIST patients.
SDH-Specific Glossary SDH-Deficient GIST Specialists Publications SDH-Deficient GIST Consortium Connect with SDH Chat Join The LRG How Can You Help? Videos/Webcasts/Webinars Member Stories SDH Fact Sheet Newly Diagnosed Checklist Starting Your [...]
About New Horizons New Horizons GIST is a conference that traditionally focuses on a large annual conference gathering over 50 representatives from 30 countries to discuss critical information about GIST that impacts the [...]
The FDA granted the approval of Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), The FDA has also granted accelerated approval to Rozlytrek for the treatment of [...]
Most GIST patients will see a surgeon at some point during their treatment. This webcast will address the issues surrounding the decision to have an operation and considers that surgical options depend on a number of factors such as tumor location, tumor size, tumor number, response to drug therapy, and risk of recurrence.
If you didn't find what you were looking for, try a new search!
